Pharmaceutical shortages continue to be an ongoing issue into 2023, with historic levels of drug scarcity adding strain to hospital budgets and interrupting patient care. The matter has gained notoriety, capturing the attention of both the White House and Congress, and is escalating to become what some experts are deeming a public health emergency. A considerable surge in new drug shortages has been observed, with an almost 30% increase from 2021 to 2022, impacting over 300 individual medications by the autumn of 2023, according to a report by Bradley Arant Boult Cummings LLP.
Finds of scarcity include generics of many commonly used oncology and chemotherapy drugs, as well as prevalent medications for conditions such as ADHD. Newer and increasingly popular medicines have not been immune to the shortages either.
The reasons behind such acuity in shortages remain multifactorial and complex, with a combination of disrupted supply chains, higher demand due to the global pandemic and regulatory challenges being amongst the significant contributors. The impact of these shortages is further resonating within and beyond the healthcare service providers, encompassing implications for law firms and international corporations as well.
The legal and corporate sectors must prepare for navigating the potentially robust regulatory landscape that could emerge as a response to this critical situation. It becomes essential for professionals in these domains to stay abreast of the developments in this area, understand the implications of the drug shortages comprehensively and implement strategies that can effectively mitigate the associated challenges. Therefore, keeping a keen eye on the evolution of this public health emergency is no longer a choice but a necessity for both healthcare and corporate legal communities.